Drug to treat hypoactive sexual desire disorder in women of ‘very limited use’
Israel re-opens restaurants, bars with 40% of country fully vaccinated
7 March 2021The UK’s PPE procurement scandal reminds us why we need ways to hold ministers to account
8 March 2021Drug to treat hypoactive sexual desire disorder in women of ‘very limited use’
An independent analysis of the medical trials which formed the final basis of approval by the US Food and Drug Administration (FDA) strongly suggests the drug bremelanotide has very limited effectiveness as a treatment for hypoactive sexual desire disorder (HSDD) in women, and that trial participants preferred a placebo.
